Literature DB >> 7839282

Intravenous and intramuscular magnesium sulphate regimens in severe pre-eclampsia.

S Chissell1, J H Botha, J Moodley, L McFadyen.   

Abstract

Patients with severe pre-eclampsia were randomised to receive magnesium sulphate according to an intramuscular (IM) (N = 9) or an intravenous (i.v.) (N = 8) regimen. The IM regimen consisted of a loading dose of 14 g (4 g i.v. and 10 g IM) followed by 5 g 4-hourly. Patients given the IV regimen received a 6 g i.v. loading dose followed by a maintenance infusion of 2 g/h. Clinical outcome, laboratory parameters and serum magnesium levels were recorded for both groups. There were no significant differences between groups with regard to clinical outcome of either mother or child. Similar average serum magnesium concentrations were produced by the regimens the only significant difference was that fluctuations in magnesium levels were greater with the IM than the i.v. regimen. None of the patients had seizures despite levels mostly below 2 mmol/l.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7839282

Source DB:  PubMed          Journal:  S Afr Med J


  7 in total

Review 1.  Magnesium sulphate and other anticonvulsants for women with pre-eclampsia.

Authors:  Lelia Duley; A Metin Gülmezoglu; David J Henderson-Smart; Doris Chou
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 2.  Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia.

Authors:  Lelia Duley; Hosam E Matar; Muhammad Qutayba Almerie; David R Hall
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

3.  Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: A randomized clinical trial.

Authors:  Ana C F Pascoal; Leila Katz; Marcela H Pinto; Carina A Santos; Luana C O Braga; Sabina B Maia; Melania M R Amorim
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

4.  Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis.

Authors:  Emily Shepherd; Rehana A Salam; Deepak Manhas; Anne Synnes; Philippa Middleton; Maria Makrides; Caroline A Crowther
Journal:  PLoS Med       Date:  2019-12-06       Impact factor: 11.069

Review 5.  An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management.

Authors:  Jeffrey Michael Smith; Richard F Lowe; Judith Fullerton; Sheena M Currie; Laura Harris; Erica Felker-Kantor
Journal:  BMC Pregnancy Childbirth       Date:  2013-02-05       Impact factor: 3.007

Review 6.  Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review.

Authors:  Emily S Bain; Philippa F Middleton; Caroline A Crowther
Journal:  BMC Pregnancy Childbirth       Date:  2013-10-21       Impact factor: 3.007

Review 7.  Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia.

Authors:  B O Okusanya; O T Oladapo; Q Long; P Lumbiganon; G Carroli; Z Qureshi; L Duley; J P Souza; A M Gülmezoglu
Journal:  BJOG       Date:  2015-11-24       Impact factor: 6.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.